Dystrophinopathies

Abstract

The dystrophinopathies fall along a spectrum of muscular dystrophy phenotypes, with variable involvement of skeletal and cardiac muscle. The diagnosis of dystrophinopathy should be suspected in any patient with a highly elevated creatine kinase level beyond the context of rhabdomyolysis secondary to toxic or metabolic myopathy. Genetic testing for dystrophinopathy is highly sensitive and specific, and identifying a proband will often lead to implications for several relatives at risk for cardiomyopathy, weakness, or anesthetic reactions. Management of the dystrophinopathies is focused primarily on supportive care, although steroid therapy has changed the natural history of Duchenne muscular dystrophy and it is now standard-of-care internationally. An exciting and ongoing area of investigation of the dystrophinopathies is focused on the potential for altering gene expression, as a way of improving muscle health and slowing the rate of muscle degeneration.

Keywords

Duchenne - Becker - dystrophinopathy - muscular dystrophy

• References

• 1 Darras BT, Menache-Stroninki CC, Hinton V, Kunkel LM. Dystrophinopathies. In: Darras BT, Jones Jr HR, Ryan MM, De Vivo DC, (Eds.). Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach. 2nd ed. San Diego, CA: Academic Press; 2015: 551-592
• 2 Darras BT, Miller DR, Urion DK. GeneReviews: Dystrophinopathies. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1119/ . Accessed July 24, 2015
• 3 Schwartz M, Hertz JM, Sveen ML, Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology 2005; 64 (9) 1635-1637
• 4 Bushby KM. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Hum Mol Genet 1999; 8 (10) 1875-1882
• 5 D'Adamo P, Fassone L, Gedeon A , et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997; 61 (4) 862-867
• 6 Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2 (12) 731-740
• 7 Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol 1997; 12 (3) 329-343
• 8 Griggs RC, Mendell JR, Miller RG. Evaluation and Treatment of Myopathies. Philadelphia, PA: F.A. Davis; 1995
• 9 Passamano L, Taglia A, Palladino A , et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol 2012; 31 (2) 121-125
• 10 Parker AE, Robb SA, Chambers J , et al. Analysis of an adult Duchenne muscular dystrophy population. QJM 2005; 98 (10) 729-736
• 11 Yazaki M, Yoshida K, Nakamura A , et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999; 42 (3) 145-149
• 12 Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998; 10 (1) 131-139
• 13 Neri M, Torelli S, Brown S , et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 2007; 17 (11–12) 913-918
• 14 Neri M, Valli E, Alfano G , et al. The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5′ X-linked dilated cardiomyopathy. BMC Med Genet 2012; 13: 20
• 15 Gavillet B, Rougier JS, Domenighetti AA , et al. Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circ Res 2006; 99 (4) 407-414
• 16 Kaspar RW, Allen HD, Ray WC , et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy. Circ Cardiovasc Genet 2009; 2 (6) 544-551
• 17 Ashwath ML, Jacobs IB, Crowe CA, Ashwath RC, Super DM, Bahler RC. Left ventricular dysfunction in Duchenne muscular dystrophy and genotype. Am J Cardiol 2014; 114 (2) 284-289
• 18 Palmucci L, Mongini T, Chiadò-Piat L, Doriguzzi C, Fubini A. Dystrophinopathy expressing as either cardiomyopathy or Becker dystrophy in the same family. Neurology 2000; 54 (2) 529-530
• 19 Juan-Mateu J, González-Quereda L, Rodriguez MJ , et al. Isolated cognitive abnormalities associated to DMD mutations. Neuromuscul Disord 2013; 23: 753
• 20 Vojinovic D, Adams HH, van der Lee SJ , et al. The dystrophin gene and cognitive function in the general population. Eur J Hum Genet 2015; 23 (6) 837-843
• 21 Wu JY, Kuban KC, Allred E, Shapiro F, Darras BT. Association of Duchenne muscular dystrophy with autism spectrum disorder. J Child Neurol 2005; 20 (10) 790-795
• 22 Hendriksen JG, Vles JS. Neuropsychiatric disorders in males with Duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive—compulsive disorder. J Child Neurol 2008; 23 (5) 477-481
• 23 Wingeier K, Giger E, Strozzi S , et al. Neuropsychological impairments and the impact of dystrophin mutations on general cognitive functioning of patients with Duchenne muscular dystrophy. J Clin Neurosci 2011; 18 (1) 90-95
• 24 Taylor PJ, Betts GA, Maroulis S , et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS ONE 2010; 5 (1) e8803
• 25 Goodnough CL, Gao Y, Li X , et al. Lack of dystrophin results in abnormal cerebral diffusion and perfusion in vivo. Neuroimage 2014; 102 (Pt 2): 809-816
• 26 Doorenweerd N, Straathof CS, Dumas EM , et al. Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy. Ann Neurol 2014; 76 (3) 403-411
• 27 Soltanzadeh P, Friez MJ, Dunn D , et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord 2010; 20 (8) 499-504
• 28 Sumita DR, Vainzof M, Campiotto S , et al. Absence of correlation between skewed X inactivation in blood and serum creatine-kinase levels in Duchenne/Becker female carriers. Am J Med Genet 1998; 80 (4) 356-361
• 29 Pegoraro E, Schimke RN, Garcia C , et al. Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 1995; 45 (4) 677-690
• 30 Hoffman EP, Arahata K, Minetti C, Bonilla E, Rowland LP. Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992; 42 (5) 967-975
• 31 Hoogerwaard EM, Bakker E, Ippel PF , et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999; 353 (9170) 2116-2119
• 32 Schade van Westrum SM, Hoogerwaard EM, Dekker L , et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology 2011; 77 (1) 62-66
• 33 Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003; 13 (2) 129-132
• 34 Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; b; 34 (2) 135-144
• 35 Deburgrave N, Daoud F, Llense S , et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007; 28 (2) 183-195
• 36 Takeshima Y, Yagi M, Okizuka Y , et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet 2010; 55 (6) 379-388
• 37 Kesari A, Pirra LN, Bremadesam L , et al. Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat 2008; 29 (5) 728-737
• 38 Hoffman EP, Fischbeck KH, Brown RH , et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988; 318 (21) 1363-1368
• 39 Hirst RC, McCullagh KJ, Davies KE. Utrophin upregulation in Duchenne muscular dystrophy. Acta Myol 2005; 24 (3) 209-216
• 40 Ferreiro V, Szijan I, Giliberto F. Detection of germline mosaicism in two Duchenne muscular dystrophy families using polymorphic dinucleotide (CA)n repeat loci within the dystrophin gene. Mol Diagn 2004; 8 (2) 115-121
• 41 Fischer C, Gross W, Krüger J, Cremer M, Vogel F, Grimm T. Modelling germline mosaicism and different new mutation rates simultaneously for appropriate risk calculations in families with Duchenne muscular dystrophy. Ann Hum Genet 2006; 70 (Pt 2): 237-248
• 42 Abbs S, Roberts RG, Mathew CG, Bentley DR, Bobrow M. Accurate assessment of intragenic recombination frequency within the Duchenne muscular dystrophy gene. Genomics 1990; 7 (4) 602-606
• 43 Ladwig D, Mowat D, Tobias V , et al. In utero fetal muscle biopsy in the diagnosis of Duchenne muscular dystrophy. Aust N Z J Obstet Gynaecol 2002; 42 (1) 79-82
• 44 Raymond FL, Whittaker J, Jenkins L, Lench N, Chitty LS. Molecular prenatal diagnosis: the impact of modern technologies. Prenat Diagn 2010; 30 (7) 674-681
• 45 Bushby K, Finkel R, Birnkrant DJ , et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; b; 9 (2) 177-189
• 46 Bushby K, Finkel R, Birnkrant DJ , et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; a; 9 (1) 77-93
• 47 Moxley III RT, Ashwal S, Pandya S , et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64 (1) 13-20
• 48 Merlini L, Cicognani A, Malaspina E , et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003; 27 (2) 222-227
• 49 Angelini C, Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31 (1) 9-15
• 50 Griggs RC, Moxley III RT, Mendell JR , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43 (3 Pt 1): 520-527
• 51 Guglieri M, Bushby K. Clinical management of dystrophinopathies: A systematic approach. In: Darras BT, Jones Jr HR, Ryan MM, De Vivo DC, (Eds.). Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach. 2nd ed. San Diego, CA: Academic Press; 2015: 593-619
• 52 Hoffman EP, Reeves E, Damsker J , et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012; 23 (4) 821-828
• 53 Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004; (2) CD003725
• 54 Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 2004; 14 (8–9) 526-534
• 55 Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12 (10) 917-925
• 56 Beenakker EA, Fock JM, Van Tol MJ , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005; 62 (1) 128-132
• 57 Escolar DM, Hache LP, Clemens PR , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77 (5) 444-452
• 58 Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007; 36 (4) 424-435
• 59 McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31 (1) 16-20
• 60 Biggar WD, Politano L, Harris VA , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004; 14 (8–9) 476-482
• 61 McDonald CM, Henricson EK, Abresch RT , et al; Cinrg Investigators. The cooperative international neuromuscular research group Duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 2013; 48 (1) 32-54
• 62 King WM, Ruttencutter R, Nagaraja HN , et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68 (19) 1607-1613
• 63 Dooley JM, Gordon KE, MacSween JM. Impact of steroids on surgical experiences of patients with Duchenne muscular dystrophy. Pediatr Neurol 2010; b; 43 (3) 173-176
• 64 Lebel DE, Corston JA, McAdam LC, Biggar WD, Alman BA. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 2013; 95 (12) 1057-1061
• 65 Schram G, Fournier A, Leduc H , et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013; 61 (9) 948-954
• 66 Barber BJ, Andrews JG, Lu Z , et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 2013; 163 (4) 1080-1084.e1
• 67 Gordon BS, Lowe DA, Kostek MC. Exercise increases utrophin protein expression in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve 2014; 49 (6) 915-918
• 68 Garrood P, Eagle M, Jardine PE, Bushby K, Straub V. Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord 2008; 18 (1) 71-73
• 69 Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000; 20 (1) 71-74
• 70 McDonald DG, Kinali M, Gallagher AC , et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 2002; 44 (10) 695-698
• 71 McAdam LC, Rastogi A, Macleod K, Douglas Biggar W. Fat embolism syndrome following minor trauma in Duchenne muscular dystrophy. Neuromuscul Disord 2012; 22 (12) 1035-1039
• 72 Medeiros MO, Behrend C, King W, Sanders J, Kissel J, Ciafaloni E. Fat embolism syndrome in patients with Duchenne muscular dystrophy. Neurology 2013; 80 (14) 1350-1352
• 73 Hsu JD, Quinlivan R. Scoliosis in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2013; 23 (8) 611-617
• 74 Mayer OH. Scoliosis and the impact in neuromuscular disease. Paediatr Respir Rev 2015; 16 (1) 35-42
• 75 Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscul Disord 2010; 20 (8) 479-492
• 76 Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990; 26 (3) 271-277
• 77 Finsterer J, Stöllberger C. The heart in human dystrophinopathies. Cardiology 2003; 99 (1) 1-19
• 78 Lin JJ, Hwang MS, Hsia SH, Chung HT, Chang YS, Lin KL. Pericardial effusion with cardiac tamponade as a cardiac manifestation of Duchenne muscular dystrophy. Muscle Nerve 2009; 40 (3) 476-480
• 79 Mavrogeni S, Papavasiliou A, Spargias K , et al. Myocardial inflammation in Duchenne muscular dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol 2010; 10: 33
• 80 Connuck DM, Sleeper LA, Colan SD , et al; Pediatric Cardiomyopathy Registry Study Group. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008; 155 (6) 998-1005
• 81 Kripe LH, Klitzner TS, Beckman RH , et al; American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 2005; 116 (6) 1569-1573
• 82 Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012; 110 (1) 98-102
• 83 Colan SD. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs. Circulation 2005; 112 (18) 2756-2758
• 84 Allen HD, Flanigan KM, Thrush PT , et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy. PLoS Curr 2013; 5: 5
• 85 Amodeo A, Adorisio R. Left ventricular assist device in Duchenne cardiomyopathy: can we change the natural history of cardiac disease?. Int J Cardiol 2012; 161 (3) e43
• 86 Khirani S, Ramirez A, Aubertin G , et al. Respiratory muscle decline in Duchenne muscular dystrophy. Pediatr Pulmonol 2014; 49 (5) 473-481
• 87 Birnkrant DJ, Bushby KM, Amin RS , et al. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010; 45 (8) 739-748
• 88 Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet 2009; 22 (5) 383-393
• 89 Chung BC, Park HJ, Yoon SB , et al. Acute gastroparesis in Duchenne's muscular dystrophy. Yonsei Med J 1998; 39 (2) 175-179
• 90 van den Engel-Hoek L, Erasmus CE, Hendriks JC , et al. Oral muscles are progressively affected in Duchenne muscular dystrophy: implications for dysphagia treatment. J Neurol 2013; 260 (5) 1295-1303
• 91 Zhu Y, Romitti PA, Caspers Conway KM , et al. for the MD STARnet. Genitourinary health in a population-based cohort of males with Duchenne and Becker muscular dystrophies. Muscle Nerve 2015; 52 (1) 22-27
• 92 Nathan A, Ganesh A, Godinez RI, Nicolson SC, Greeley WJ. Hyperkalemic cardiac arrest after cardiopulmonary bypass in a child with unsuspected duchenne muscular dystrophy. Anesth Analg 2005; 100 (3) 672-674
• 93 Hayes J, Veyckemans F, Bissonnette B. Duchenne muscular dystrophy: an old anesthesia problem revisited. Paediatr Anaesth 2008; 18 (2) 100-106
• 94 Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109 (4) 1043-1048
• 95 Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104 (4) 375-381
• 96 Kimura S, Ito K, Miyagi T , et al. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy. Brain Dev 2005; 27 (6) 400-405
• 97 Wagner KR, Hamed S, Hadley DW , et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49 (6) 706-711
• 98 Dunant P, Walter MC, Karpati G, Lochmüller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 2003; 27 (5) 624-627
• 99 Malik V, Rodino-Klapac LR, Viollet L , et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010; 67 (6) 771-780
• 100 Welch EM, Barton ER, Zhuo J , et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447 (7140) 87-91
• 101 Bushby K, Finkel R, Wong B , et al; PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50 (4) 477-487
• 102 Finkel R, Wong B, Bushby K , et al. Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscul Disord 2010; 20: 656-657
• 103 Alter J, Lou F, Rabinowitz A , et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12 (2) 175-177
• 104 Wilton SD, Fletcher S. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Curr Pharm Des 2010; 16 (8) 988-1001
• 105 Goemans NM, Tulinius M, van den Akker JT , et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364 (16) 1513-1522
• 106 Mendell JR, Rodino-Klapac LR, Sahenk Z , et al; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74 (5) 637-647
• 107 Voit T, Topaloglu H, Straub V , et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014; 13 (10) 987-996
• 108 Al-Zaidy S, Rodino-Klapac L, Mendell JR. Gene therapy for muscular dystrophy: moving the field forward. Pediatr Neurol 2014; 51 (5) 607-618
• 109 Gregorevic P, Allen JM, Minami E , et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12 (7) 787-789
• 110 van Deutekom JC, van Ommen GJ. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 2003; 4 (10) 774-783
• 111 Mendell JR, Campbell K, Rodino-Klapac L , et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363 (15) 1429-1437
• 112 Arechavala-Gomeza V, Kinali M, Feng L , et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010; 20 (5) 295-301
• 113 Moore MJ, Flotte TR. Autoimmunity in a genetic disease—a cautionary tale. N Engl J Med 2010; 363 (15) 1473-1475
• 114 Balagopal P, Olney R, Darmaun D , et al. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab 2006; 290 (3) E530-E539
• 115 Fenichel G, Pestronk A, Florence J, Robison V, Hemelt V. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 48 (5) 1225-1226
• 116 Fenichel GM, Griggs RC, Kissel J , et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001; 56 (8) 1075-1079
• 117 Blau HM. Cell therapies for muscular dystrophy. N Engl J Med 2008; 359 (13) 1403-1405
• 118 Markert CD, Atala A, Cann JK , et al. Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy. PM R 2009; 1 (6) 547-559
• 119 Mendell JR, Kissel JT, Amato AA , et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995; 333 (13) 832-838
• 120 Walter MC, Lochmüller H, Reilich P , et al. Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study. Neurology 2000; 54 (9) 1848-1850
• 121 Louis M, Lebacq J, Poortmans JR , et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003; 27 (5) 604-610
• 122 Tarnopolsky MA, Mahoney DJ, Vajsar J , et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004; 62 (10) 1771-1777
• 123 Escolar DM, Buyse G, Henricson E , et al; CINRG Group. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005; 58 (1) 151-155
• 124 Spurney CF, Rocha CT, Henricson E , et al; Cooperative International Neuromuscular Research Group Investigators. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 2011; 44 (2) 174-178
• 125 Buyse GM, Goemans N, Henricson E , et al for the Cooperative International Neuromuscular Research Group Investigators. CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy. Eur J Paediatr Neurol 2007; 11 (6) 337-340
• 126 Kirschner J, Schessl J, Schara U , et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 2010; 9 (11) 1053-1059
• 127 Minetti GC, Colussi C, Adami R , et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006; 12 (10) 1147-1150
• 128 Leung DG, Herzka DA, Thompson WR , et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol 2014; 76 (4) 541-549
• 129 Witting N, Kruuse C, Nyhuus B , et al. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. Ann Neurol 2014; 76 (4) 550-557
• 130 Escolar DM, Zimmerman A, Bertorini T , et al. Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial. Neurology 2012; 78 (12) 904-913
• 131 Nelson MD, Rader F, Tang X , et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 2014; 82 (23) 2085-2091
• 132 Martin EA, Barresi R, Byrne BJ , et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012; 4 (162) 162ra155
• 133 Bogdanovich S, Krag TO, Barton ER , et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420 (6914) 418-421
• 134 Wagner KR, Fleckenstein JL, Amato AA , et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63 (5) 561-571
• 135 Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: a 30-year population-based incidence study. Clin Pediatr (Phila) 2010; a; 49 (2) 177-179
• 136 Tangsrud SE, Halvorsen S. Child neuromuscular disease in southern Norway. The prevalence and incidence of Duchenne muscular dystrophy. Acta Paediatr Scand 1989; 78 (1) 100-103
• 137 Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 2013; 21 (10) 1049-1053
• 138 Bushby KM, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet 1991; 337 (8748) 1022-1024